A significant drop in the screening, diagnosis and treatment of genitourinary cancers was observed during the early months of the COVID-19 pandemic. Hereafter, a progressive recovery was observed. Notably, the screening rate for...
Read More
An ongoing open-label, randomized phase 3 trial (NCT04736706) will determine the efficacy of the...
Read MoreResults from the ATLANTIS trial platform indicate that rucaparib could play a role in the maintenance treatment of metastatic urothelial carcinoma with a DNA repair deficiency that has responded to first-line platinum-based...
Read More
Updated data from the KEYNOTE-564 trial shows pembrolizumab disease-free survival persists long...
Read More
Combination treatment with nivolumab plus axitinib has achieved a high response rate in...
Read More
Biomarker analysis of the phase 2 TITAN-RCC trial identified specific immune cell-related...
Read More
Results of the NeoAvAx trial indicate that the neoadjuvant combination of avelumab plus axitinib...
Read MoreIndividual Accountability ASCO is committed to maintaining the health and safety of all ASCO Genitourinary Cancers Symposium attendees. We will be reviewing the latest Centers for Disease Control and Prevention and World Health...
Read MoreActive surveillance (AS) may be used effectively in a subgroup of patients(pts) with metastatic renal cell carcinoma (RCC) and indolent disease to postpone the commencement of systemic treatment without affecting long-term...
Read MoremRCC was linked to a high incidence of distress, a high degree of symptom load, and a wide range of quality-of-life impairments. A smartphone application aimed at enhancing mindfulness has been developed from a Mindfulness-Based...
Read MoreIn recent years, the overall survival from metastatic renal cell carcinoma (RCC) has improved, mainly in part due to immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI). TKI and ICI had distinct and...
Read MoreLenvatinib (lenva) + pembrolizumab (pembro) demonstrated encouraging antitumor activity and controllable safety characteristics in treatment-naive (n=23) or earlier cured metastatic RCC (n=105, initially medicated with immune...
Read MoreThursday, Feb 17: Exhibits Open 10:00 AM – 9:45 PM EST Novel Treatment Implementation: Prostate-Specific Membrane Antigen Targeting and Beyond Primary Track: Prostate Cancer 10:45 AM – 12:30 PM EST Optimizing Management of...
Read MoreProgram at a Glance • Highly interactive sessions with multidisciplinary perspectives on new, innovative findings in the study, diagnosis, and treatment of GU malignancies. • Presentation of the latest novel science and...
Read More
Guidelines recommend biomarker testing, but is it done? Next-generation sequencing (NGS) may help...
Read More
Benefit driven by 29% relative reduction in heart failure hospitalization SGLT2 inhibitors were...
Read MoreWith an updated median follow-up of 34.1 months, the 30-month progression-free survival (PFS) was 80.5% with ibrutinib plus venetoclax versus 35.8% for chlorambucil plus obinutuzumab in elderly or unfit patients with chronic...
Read MoreClonal hematopoiesis of indeterminate potential (CHIP) was related to decreased risk of Alzheimer’s disease (AD) and AD neuropathological changes. Mutated hematopoietic stem cells were detected in the brains of CHIP carriers....
Read MoreTherapy de-escalation in patients with acute lymphoblastic leukemia (ALL) and a low-risk minimal residual disease (MRD) profile was safe, 10-year follow-up results of the UKALL 2003 trial show. Patients with a high-risk MRD...
Read MoreA combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia (AML). Patients with RAS/MAPK and FLT3-F691L mutations...
Read More
